Visceral Pain Market Report 2026

The visceral pain market size has grown strongly in recent years. It will grow from $14.82 billion in 2025 to $15.7 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to increasing prevalence of gastrointestinal and pelvic disorders, wider use of NSAIDs and calcium channel blockers, improved clinical recognition of visceral pain conditions, expansion of hospital-based pain management services, availability of diversified drug classes.

The visceral pain market size is expected to see strong growth in the next few years. It will grow to $19.6 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to increasing demand for personalized pain therapies, rising focus on chronic pain management, expansion of precision medicine approaches, growing adoption of advanced diagnostic tools, increasing investments in non-opioid drug development. Major trends in the forecast period include increasing adoption of targeted pain management therapies, rising use of multimodal drug combinations, growing focus on non-opioid treatment options, expansion of personalized visceral pain management, enhanced emphasis on early diagnosis and intervention.

The rising demand for analgesics is expected to drive the growth of the visceral pain market going forward. Analgesics are medications that relieve pain by reducing or blocking the perception of pain signals in the brain. They help manage visceral pain by targeting the nervous system and modulating pain signals originating from internal organs. For instance, in April 2024, according to the New England Journal of Medicine, a UK-based weekly medical journal, over 53,600 clinicians were prescribing buprenorphine by December 2023, marking an increase of 11,500 prescribers compared to December 2022. Therefore, the rising demand for analgesics is fueling the growth of the visceral pain market.

Major companies operating in the chronic pain market are focusing on conducting clinical trials to develop innovative products, such as NOP receptor agonists, to provide effective pain relief while potentially minimizing the risks associated with opioid-based treatments. NOP receptor agonists are compounds that activate the nociceptin/orphanin FQ peptide receptor, which modulates pain signaling in the nervous system. They help reduce chronic and visceral pain without the high risk of addiction or severe side effects typically linked to traditional opioids. For instance, in October 2024, Grünenthal GmbH, a Germany-based pharmaceutical company, initiated a first-in-human Phase I clinical trial enrolling 90 healthy participants to evaluate the safety, tolerability, and pharmacokinetics of its novel NOP receptor agonist. This study aims to assess the investigational compound’s potential to provide potent and safe pain relief across chronic pain conditions, offering a novel therapeutic approach for both somatic and visceral pain.

In April 2023, Marksans Pharma, an India-based pharmaceutical company, acquired the India manufacturing facility of Teva Pharmaceuticals for an undisclosed sum. This acquisition gives Marksans a 47,597-square-meter facility, enabling it to double its production capacity in India from 8 billion units annually. The expanded capacity will support the production of tablets, hard and soft gel capsules, ointments, liquids, and creams. Teva Pharmaceuticals is an Israel-based provider of treatments for visceral pain.

Major companies operating in the visceral pain market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co.Inc., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Endo International PLC, Grünenthal GmbH, Glenmark Pharmaceuticals Limited, Hisamitsu Pharmaceutical Co. Ltd., Chromocell Corporation, Addex Therapeutics Ltd.

North America was the largest region in the visceral pain market in 2025. The regions covered in the visceral pain market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the visceral pain market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the visceral pain market by increasing costs of imported active pharmaceutical ingredients, specialty excipients, and advanced drug manufacturing equipment used across NSAIDs, calcium channel blockers, and adjunct therapies. Pharmaceutical manufacturers and healthcare providers in North America and Europe are most affected due to reliance on global API supply chains, while Asia-Pacific faces cost pressure in drug formulation and export activities. These tariffs are contributing to higher drug prices and supply chain complexity. However, they are also encouraging localized API production, regional manufacturing investments, and long-term supply chain diversification for pain management therapies.

The visceral pain market research report is one of a series of new reports that provides visceral pain market statistics, including visceral pain industry global market size, regional shares, competitors with a visceral pain market share, detailed visceral pain market segments, market trends and opportunities, and any further data you may need to thrive in the visceral pain industry. This visceral pain market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Visceral pain refers to discomfort originating from internal organs such as the stomach, bladder, uterus, or rectum. It can result from factors including inflammation, menstrual cramps, organ swelling or stretching, blockages, reduced blood flow, and tumors, particularly in the pelvis or abdomen. Visceral pain is often accompanied by symptoms such as nausea, sweating, or a rapid heartbeat.

The main drug classes for visceral pain include calcium channel blockers, nonsteroidal anti-inflammatories (NSAIDs), and others. Calcium channel blockers (CCBs) are medications that primarily influence the movement of calcium ions into the cells of the heart and blood vessels. Indications for these drugs include interstitial cystitis, Crohn’s disease, irritable bowel syndrome, chronic prostatitis, and others. They are used by end users such as hospitals, home care providers, specialty clinics, and other healthcare facilities.

The visceral pain market consists of sales of opioids, anticonvulsants, gabapentin, and pregabalin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.